Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.

The American journal of psychiatry - 1 Mar 2006

Lencz Todd, Robinson Delbert G, Xu Ke, Ekholm Jenny, Sevy Serge, Gunduz-Bruce Handan, Woerner Margaret G, Kane John M, Goldman David, Malhotra Anil K

Abstract excerpt

OBJECTIVE: All antipsychotics act on the dopamine D(2) receptor. The present study extends prior pharmacogenetic investigations of the D(2) receptor gene (DRD2) by examining, in first-episode schizophrenia patients, promoter region variation as a predictor of response time to two first-line atypical antipsychotics. METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Benzodiazepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Olanzapine

Share to Pharmacogenetics

Share to Receptors, Dopamine D2

Share to Risperidone

Share to Schizophrenia

Share to Schizophrenic Psychology

Source

Identifiers

PMID: 16513877
DOI: 10.1176/appi.ajp.163.3.529

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.PMID 16513877Read ↗

Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.Semantic proximity Read ↗

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.Semantic proximity Read ↗

Treatment Response and GWAS Risk Allele rs2514218 (C) of the Dopamine D2 Receptor Gene in Inpatients with Schizophrenia.Semantic proximity Read ↗

A novel DRD2 single-nucleotide polymorphism associated with schizophrenia predicts age of onset: HapMap tag-single-nucleotide polymorphism analysis.Semantic proximity Read ↗

Pharmacogenetics of second-generation antipsychotics.Semantic proximity Read ↗

Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.Semantic proximity Read ↗

Dopamine Receptor D2 gene Polymorphisms rs2005313, rs4274224, and rs4938019 in Pakistani Patients with Schizophrenia:a Diagnostic Tool for Schizophrenia.Semantic proximity Read ↗

Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain.Semantic proximity Read ↗

DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophreniaSemantic proximity Read ↗

Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response.Semantic proximity Read ↗

Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes.Semantic proximity Read ↗

No genetic association between dopamine D1 receptor gene and [early onset] schizophrenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.